RCPT up +0.93% percent Today $RCPT High is at 112.17 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:40 PM

RCPT up +0.93% percent Today $RCPT High is at 112.17 and the Low 108.25 with current volume of 242,122.

Recent News posted below.

Receptos Inc RCPT other info.
http://investorshangout.com/Receptos-Inc-RCPT-87962/

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.74 (+0.50)

Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST

RCPT: 109.74 (+0.50)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.74 (+0.50)

Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST

RCPT: 109.74 (+0.50)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.74 (+0.50)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.74 (+0.50)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.07 (+0.70), WMGI: 27.79 (-0.16), CFN: 57.42 (+0.14), UTHR: 125.01 (+0.80), RCPT: 109.74 (+0.50), WMGIZ: 4.40 (+0.09)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.74 (+0.50)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 51.41 (+1.24), PTLA: 27.50 (+0.11), RCPT: 109.74 (+0.50), IG: 9.57 (+0.12)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 27.90 (+1.27), ECHO: 27.90 (+0.57), LAYN: 7.60 (+0.08), NVAX: 5.13 (+0.18), SCYX: 9.46 (+0.46), RCPT: 109.74 (+0.50), TRNX: 25.94 (+0.44), IDTI: 18.11 (+0.38), SANM: 25.36 (-0.24)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.35 (-0.04), KSS: 56.79 (-0.43), MU: 32.99 (-0.02), PFE: 30.25 (+0.33), HAL: 53.47 (-0.39), AMGN: 162.61 (+2.36), NQ: 7.37 (+0.19), RGC: 22.43 (+0.28), MS: 35.75 (+0.09), MSG: 75.01 (-0.14), NVAX: 5.13 (+0.18), CQB: 14.44 (+0.01), SRPT: 15.87 (-0.25), RCPT: 109.74 (+0.50), TWTR: 39.86 (-0.45), PTIE: 1.70 (-0.01)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 162.61 (+2.36), RCPT: 109.74 (+0.50), NVS: 92.56 (+0.80)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.85 (-0.08), AMKR: 6.35 (-0.04), VTAE: 16.48 (+2.04), ASTI: 1.86 (-0.12), CLF: 11.34 (+0.17), LMNX: 18.11 (+0.07), IDTI: 18.11 (+0.38), HNR: 3.02 (-0.15), VDSI: 27.90 (+1.27), DCO: 23.69 (-0.35), MDCO: 24.51 (-0.08), SCYX: 9.46 (+0.46), VGGL: 1.60 (+0.02), RCPT: 109.74 (+0.50), IBIO: 1.24 (+0.08), SNY: 46.30 (+0.61), TWTR: 39.86 (-0.45), DPW: 1.60 (-0.07), MERU: 4.05 (+0.04), SANM: 25.36 (-0.24)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.90 (+0.70), RCPT: 109.74 (+0.50), ABBV: 63.65 (+2.15)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:13AM CDT

KSS: 56.79 (-0.43), FRO: 1.38 (-0.02), ASTI: 1.86 (-0.12), TRNX: 25.94 (+0.44), CVLT: 48.08 (+0.02), UBS: 17.12 (+0.06), BWLD: 159.02 (+1.51), HASI: 13.71 (+0.08), COH: 33.84 (+0.18), VDSI: 27.90 (+1.27), MSG: 75.01 (-0.14), NVO: 43.44 (-0.25), ACI: 2.61 (-0.25), RCPT: 109.74 (+0.50), TWTR: 39.86 (-0.45), SNY: 46.30 (+0.61), FOLD: 6.19 (+0.47), NE: 21.15 (-0.68)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 174.23 (-1.58), VDSI: 27.90 (+1.27), RCPT: 109.74 (+0.50), BP: 41.97 (-0.09), TWTR: 39.86 (-0.45), AET: 83.79 (+1.50)

Receptos up premarket on UC trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:09AM CDT

RCPT: 109.74 (+0.50)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.74 (+0.50)

Receptos lead product successful in Phase 2 for UC at higher dose
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 5:25PM CDT

RCPT: 109.74 (+0.50)

Receptos Inc. (RCPT) Stock Research Links

RCPT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GreenCore AI Agents Shatter Monthly Record in Ops Surge

Dispatch from the Digital Trenches GreenCore Solutions Corp. (GSC) just made a bit of a splash with those numbers any company would salivate over. We're talking 24.5 million AI agent transactions in just one month. If that doesn't jolt your morning coffee, not sure what will. AI Agents Getting Busy For those out of the loop, GSC isn't your run-of-the-mill tech outfit....

VEVOR's Labor Day Salute to Home DIY Warriors

Celebrating the DIY Spirit When most folks think of Labor Day, they picture grilling and lounging. But there's a whole crew out there wielding hammers and paintbrushes, making the most of their long weekend. That's right, Labor Day isn't just rest for some; it's a roll-up-your-sleeves and get it done kind of holiday, and VEVOR is tipping its hat to those folks. Home...

Freeport-McMoRan Hit with Legal Probe: What's Next?

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...

Shenzhen Media Push: Shaping Asia-Pacific's Future

A Metamorphosis in Shenzhen You ever hear about a place that rockets from obscurity to global significance in the blink of an eye? Well, Shenzhen, China is that place. Forty years ago, it was just a quaint fishing village. Fast forward a few decades, and you've got yourself an international powerhouse—a testament to China's rapid development strategy. Shenzhen is now...

Sarepta Under Scrutiny: KSF's Investigation Deepens

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Frederick’s Heartbeat: 2026 Sass LOCAL Issue Drops

Frederick’s Local Scene Takes the Spotlight Ever strolled down a street and felt the neighborhood pulse through your bones? That vibe—you know it if you've been to Frederick, Maryland. And that very essence is captured in the latest edition of Sass Magazine's LOCAL issue. This isn't just your garden-variety publication; it's a window into the heart of Frederick...

Delisting Gray Wolf Sparks Heated Hunter Nation Debate

Unraveling the Gray Wolf Controversy What are we looking at here—political maneuvering wrapped in a fur coat? Trump's executive order is making some calls I didn’t see coming. By pushing to delist the gray wolf from the Endangered Species Act (ESA), he's stirring up a mix of joy, outrage, and a boatload of debate about environmental ethics, conservation priorities,...

Planes Moving Seizing Growth in Cincinnati-Dayton Corridor

Strategic Movements in the Logistics Arena Putting wheels to brilliant moves, Planes Moving & Storage of Dayton is tweaking its operations with a big change in scenery—expect the dynamics in the Cincinnati-Dayton corridor to really start popping. Now, if you’ve ever skimmed the logistics world, you know it’s a place where shuffles can be seismic, and relocating...

Actinium Pharma Unveils Plans at Key Investor Conference

Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...